Markers of Osteoarthritis: A Review of the Literature

Veterinary Surgery

Volumn 24, Issue 3, 1995, Pages 255-262

  RORVIK, ARNE MAGNUS ^a,b   GRONDAHL, ANN MARGARET ^a,b  

^a NORWEGIAN UNIVERSITY OF LIFE SCIENCES   (Norway)

^b Department of Large Animal Clinical Sciences ^*  (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL; CARTILAGE; CHEMISTRY; CYTOLOGY; HUMAN; OSTEOARTHRITIS; REVIEW; SYNOVIAL FLUID;

ANIMAL; BIOLOGICAL MARKERS; CARTILAGE; HUMAN; OSTEOARTHRITIS; SUPPORT, NON-U.S. GOV'T; SYNOVIAL FLUID;

EID: 0029298807     PISSN: 01613499     EISSN: 1532950X     Source Type: Journal    
DOI: 10.1111/j.1532-950X.1995.tb01327.x     Document Type: Review

References (74)

1. Radiologic and patho‐anatomic changes in the distal joints and the phalanges of the standardised horse
2. Degenerative joint disease
3. Diseases of joints, tendons, ligaments, and related structures. Specific diseases of joints
4. Pathologic findings and pathogenesis of racetrack injuries
5. Osteoarthritis: Clinical and research perspective
6. Cartilage matrix metabolism in osteoarthritis: Markers in synovial fluid, serum, and urine
7. Joint cartilage markers in synovial fluid in human osteoarthritis
8. Proteoglycan fragments in joint fluid. Influence of arthrosis and inflammation
9. Development of criteria for the classification and reporting of osteoarthritis: Classification of osteoarthritis in the knee
10. The “clearance” of macromolecular substances such as cartilage markers from synovial fluid and serum
11. Neutral proteases capable of proteoglycan digesting activity in osteoarthritic and normal human articular cartilage
12. Imbalance between the mechanisms of activation and inhibition of metallo‐proteases in the early lesions of experimental osteoarthritis
13. Role and regulation of metalloproteases in connective tissue turnover
14. Metalloproteinases and tissue damage
15. The cartilage collagens and joint degeneration
16. Metalloproteinases. tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis
17. LDH and LDH isoenzymes of synovial fluid in the horse
18. Synovialundersokningar vid olika ledforandringar hos hast
19. Cytokines: Molecular and biological characteristics
20. In vivo studies of articular tissue damage mediated by catabolin/inter‐leukin 1
21. The mechanism of cartilage degradation in osteoarthritic joints
22. Interleukin‐1 ‐induced interleukin–6 is required for the inhibition of proteoglycan synthesis by interleukin–1 in human articular cartilage
23. Inhibition of interleukin–1‐induced collagenase production in human articular chondrocytes in vitro by recombinant human interferon‐gamma
24. Elevated synovial fluid levels of Interleukin–6 and tumor necrosis factor associated with early experimental canine osteoarthritis
25. Balance between swelling pressure and collagen tension in normal and degenerate cartilage
26. Matrix metalloproteinases and their inhibitors in connective tissue remodelling
27. The structure of aggrecan fragments in human synovial fluid
28. Proteoglycans of joint cartilage‐Structure, function, turnover and role as markers of joint disease
29. Structure and biology of cartilage and bone matrix noncollagenous macromolecules
30. Demonstration of increased proteoglycan turnover in cartilage explants from dogs with experimental osteoarthritis
31. Secretion of higher levels of active proteoglycanases from human osteoarthritic chondrocytes
32. A method for the quantification of cartilage proteoglycan structures liberated to the synovial fluid during developing degenerative joint disease
33. Glycosaminoglycans in horses with osteoarthritis
34. Spectrophotometric measurement of proteoglycans in osteoarthritic synovial fluid
35. Quantification of keratan sulphate in blood as a marker of cartilage catabolism
36. Synovial fluid analysis of two groups of proteoglycan epitopes distinguishes early and late cartilage lesions
37. Identification of cartilage matrix glycoprotein in synovial fluid in human osteoarthritis
38. Cartilage matrix glycoprotein is present in serum of dogs with experimental osteoarthritis
39. Increased serum concentrations of cartilage oligomeric matrix protein. A prognostic marker in early rheumatoid arthritis
40. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis
41. Fibronectin, cartilage, and osteoarthritis
42. Fibronectin as a marker for osteoarthritis
43. Fibronectin fragments in osteoarthritic synovial fluid
44. A new biochemical marker for joint injury. Analysis of YK.L–40 in serum and synovial fluid
45. Protein traffic in human synovial effusions
46. Collagen cross‐linking in human bone and articular cartilage. Age‐related changes in the content of mature hydroxypyridinum residues
47. Type XI collagendegrading activity in human osteoarthritic cartilage
48. Osteoarthritis: Biochemical aspects
49. The degradation of type II collagen in rheumatoid arthritis: An immunoelectron microscopic study
50. Antibodies to canine collagen types I and II in dogs with spontaneous cruciate ligament rupture and osteoarthritis
51. Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue diseases, and chronic inflammatory syndromes
52. Anti‐type II collagen antibody in naturally occurring canine joint diseases
53. Increased damage to type II collagen in osteoarthritic articular cartilage detected by new immunoassey
54. Urinary hydroxy‐pyridinum crosslinks provide indices of cartilage and bone involvement in arthritic diseases
55. Urinary excretion of pyridinum crosslinks of collagen correlated with joint damage in arthritis
56. Relationship of urinary pyridinum crosslinks to disease extent and activity of osteoarthritis
57. Serum antibodies against chondrocyte cell surface proteins in osteoarthritis and rheumatoid arthritis
58. Estimation of serum anticollagen and antibodies against chondrocyte membrane fraction; their clinical diagnostic significance in osteoarthritis
59. Association of radiographic changes of osteoarthritis, symptoms, and synovial fluid particles in 300 knees
60. Quantitation of chondroitin 4‐sulphate and chondroitin 6‐sulphate in pathologic joint fluid
61. Modulation of native chondroitin sulphate structure in tissue development and disease
62. The quantitation of a native chondroitin sulphate epitope in synovial fluid lavages and articular cartilage from canine experimental osteoarthritis and disuse atrophy
63. Synovial fluid analyses detect and differentiate proteoglycan metabolism in canine experimental models of osteoarthritis and disuse atrophy
64. Changes in cartilage metabolism in arthritis are reflected by altered serum and synovial fluid levels of the cartilage proteoglycan aggrecan. Implications for pathogenesis
65. Osteoarthritis‐related changes in human articular cartilage. An immunologic study
66. Molecular markers of processes in cartilage in joint disease
67. Procollagen type III amino‐terminal peptide in serum and synovial fluid of dogs with hip dysplasia and coxarthrosis
68. Molecular markers of joint disease: Significance of the levels of type II collagen C‐propeptide, chondroitin 4S/6S and TIMP in synovial fluid
69. Type X collagen synthesis in human osteoarthritic cartilage
70. Genetic linkage of a polymorphism in the type II procollagen gene (COL2A1) to primary osteoarthritis associated with mild chondrodysplasia
71. Epiphyseal growth and osteoarthritis in blotchy mice
72. Imaging, arthroscopy, and markers in osteoarthritis
73. A pessimistic view of serologic markers for diagnosis and management of osteoarthritis. Biochemical, immunologic and clinicopathologic barriers